“Long‐term” is getting longer for children receiving liver transplantation grafts
Pamela L. Valentino – 31 July 2022
Waitlist mortality in pediatric liver transplantation: The goal is zero
George V. Mazariegos, Kyle A. Soltys, Emily R. Perito – 31 July 2022
A new approach to manage aberrant hepatic arteries in liver transplantation: Is one better than two?
Quirino Lai, Jan Lerut – 30 July 2022
HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma
Na Sun, Ceng Zhang, Yi‐Te Lee, Benjamin V. Tran, Jing Wang, Hyoyong Kim, Junseok Lee, Ryan Y. Zhang, Jasmine J. Wang, Junhui Hu, Zhicheng Zhang, Manaf S. Alsudaney, Kuan‐Chu Hou, Hubert Tang, Tiffany X. Zhang, Icy Y. Liang, Ziang Zhou, Mengxiang Chen, Angela Hsiao‐Jiun Yeh, Wenyuan Li, Xianghong Jasmine Zhou, Helena R. Chang, Steven‐Huy B. Han, Saeed Sadeghi, Richard S. Finn, Sammy Saab, Ronald W. Busuttil, Mazen Noureddin, Walid S. Ayoub, Alexander Kuo, Vinay Sundaram, Buraq Al‐Ghaieb, Juvelyn Palomique, Kambiz Kosari, Irene K. Kim, Tsuyoshi Todo, Nicholas N.
Improving DCD liver utilization by challenging the status quo
Mark J. Hobeika, Flavio E. Baio, Ashish Saharia – 29 July 2022
Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis
Jasmohan S. Bajaj, K. Rajender Reddy, Puneeta Tandon, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jacqueline G. O'Leary, Florence Wong, Jennifer Lai, Hugo Vargas, Paul J. Thuluvath, Ram M. Subramanian, Marcela Pena‐Rodriguez, Masoumeh Sikaroodi, Leroy R. Thacker, Patrick M. Gillevet – 29 July 2022 – Cirrhosis is complicated by a high rate of nosocomial infections (NIs), which result in poor outcomes and are challenging to predict using clinical variables alone. Our aim was to determine predictors of NI using admission serum metabolomics and gut microbiota in inpatients with cirrhosis.
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient‐reported quality of life
Laura Heath, Paul Aveyard, Jeremy W. Tomlinson, Jeremy F. Cobbold, Dimitrios A. Koutoukidis – 27 July 2022 – Nonalcoholic steatohepatitis (NASH) is a prevalent chronic disease that is associated with a spectrum of liver fibrosis and can lead to cirrhosis. Patients with NASH report lower health‐related quality of life (HRQoL) than the general population. It remains uncertain how changes in histologic severity are associated with changes in HRQoL.
Liver CHOP‐and‐change stress response
Pasquale Piccolo, Nicola Brunetti‐Pierri – 27 July 2022
Reduction in gut‐derived MUFAs via intestinal stearoyl‐CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma
Simon Ducheix, Elena Piccinin, Claudia Peres, Oihane Garcia‐Irigoyen, Justine Bertrand‐Michel, Allan Fouache, Marica Cariello, Jean‐Marc Lobaccaro, Hervé Guillou, Carlo Sabbà, James M. Ntambi, Antonio Moschetta – 27 July 2022 – Nonalcoholic fatty liver disease (NAFLD) is defined by a set of hepatic conditions ranging from steatosis to steatohepatitis (NASH), characterized by inflammation and fibrosis, eventually predisposing to hepatocellular carcinoma (HCC).
Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients
Manuel Mendizabal, Nicolás Ducasa, Paula Benencio, Margarita Anders, Fernando Cairo, Manuel Barbero, Patricia Etcheves, Adriana Alter, Giampaolo Scarton, Juan G. Abraldes, Mirna Biglione, Ezequiel Mauro – 27 July 2022 – Knowledge of the immunogenicity of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in liver transplant recipients (LTRs) is mainly limited to messenger RNA (mRNA)‐based types.